1. Home
  2. GAB vs SRPT Comparison

GAB vs SRPT Comparison

Compare GAB & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Equity Trust Inc. (The)

GAB

Gabelli Equity Trust Inc. (The)

N/A

Current Price

$5.22

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

N/A

Current Price

$17.66

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GAB
SRPT
Founded
1986
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
GAB
SRPT
Price
$5.22
$17.66
Analyst Decision
Hold
Analyst Count
0
24
Target Price
N/A
★ $21.73
AVG Volume (30 Days)
1.0M
★ 2.5M
Earning Date
01-01-0001
11-02-2026
Dividend Yield
★ 10.91%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 2.99
Revenue
N/A
★ $2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$6.25
Revenue Growth
N/A
★ 15.58
52 Week Low
$5.21
$14.68
52 Week High
$6.37
$25.32

Technical Indicators

Market Signals
Indicator
GAB
SRPT
Relative Strength Index (RSI) 31.14 40.85
Support Level N/A $15.19
Resistance Level $5.72 $18.16
Average True Range (ATR) 0.09 0.98
MACD -0.02 -0.36
Stochastic Oscillator 3.77 10.73

Price Performance

Historical Comparison
GAB
SRPT

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: